Pyxis Oncology (PYXS) Operating Expenses (2020 - 2026)

Pyxis Oncology (PYXS) has reported Operating Expenses for 7 consecutive years, with $26.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 15.15% year-over-year to $26.0 million in Q2 2026; TTM through Jun 2026 was $101.4 million, a 7.28% decrease from a year earlier, with the FY2025 full-year figure at $98.3 million, down 6.94% from the prior year.
• Operating Expenses was $26.0 million for Q2 2026 at Pyxis Oncology, down from $29.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $40.1 million in Q4 2024 and troughed at $17.8 million in Q4 2023.
• A 5-year average of $25.6 million and a median of $23.8 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 333.02% in 2022 and sank 53.21% in 2023, its largest moves.
• Over 5 years, Operating Expenses stood at $38.0 million in 2022, then slumped by 53.21% to $17.8 million in 2023, then soared by 125.52% to $40.1 million in 2024, then slipped by 26.79% to $29.3 million in 2025, then dropped by 11.4% to $26.0 million in 2026.
• The last three Operating Expenses figures came in at $26.0 million (Q2 2026), $29.3 million (Q4 2025), and $23.5 million (Q3 2025), per Business Quant data.